Condition: Migraine · Sponsor: AbbVie
Migraine is a neurological disease characterized by moderate or severe headaches, associated with nausea, vomiting, and/or sensitivity to light and sound. This study will assess changes in migraine attack severity for adult participants treating with oral ubrogepant across migraine attacks. Ubrogepant is a drug that is approved for the acute treatment of migraine in adults. Approximately 189 participants will be enrolled in approximately 15 sites across the US. Participants will receive ubrogepant as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for up to 13 weeks. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
This description comes directly from the study's public registry record.
Krystal Spenta · 844-663-3742 · krystal.spenta@abbvie.com
Always discuss trial participation with your own doctor first.
| Neurology and Pain Specialty Center /ID# 278508 | Aliso Viejo, California, United States | Recruiting |
| Chicago Headache Center & Research Inst /ID# 272345 | Naperville, Illinois, United States | Recruiting |
| Tri City Research Center, LLC /ID# 278800 | Grand Island, Nebraska, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07310290